Lannett Company, Inc. (LCI) Receives $13.56 Consensus PT from Brokerages

Lannett Company, Inc. (NYSE:LCI) has received an average rating of “Hold” from the nine research firms that are covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $13.56.

A number of brokerages recently issued reports on LCI. Zacks Investment Research upgraded shares of Lannett from a “hold” rating to a “strong-buy” rating and set a $9.75 price target on the stock in a research note on Saturday, February 9th. SunTrust Banks began coverage on shares of Lannett in a research note on Tuesday, March 19th. They issued a “hold” rating and a $9.00 price target on the stock. Finally, ValuEngine cut shares of Lannett from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th.

In other Lannett news, CEO Timothy C. Crew bought 4,000 shares of the firm’s stock in a transaction on Monday, February 11th. The stock was acquired at an average price of $8.48 per share, with a total value of $33,920.00. Following the transaction, the chief executive officer now owns 45,988 shares in the company, valued at $389,978.24. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Patrick G. Lepore bought 25,000 shares of the firm’s stock in a transaction on Tuesday, February 12th. The stock was acquired at an average cost of $8.93 per share, with a total value of $223,250.00. The disclosure for this purchase can be found here. 12.57% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of the business. Wells Fargo & Company MN increased its position in shares of Lannett by 62.7% during the 3rd quarter. Wells Fargo & Company MN now owns 91,087 shares of the company’s stock valued at $432,000 after purchasing an additional 35,112 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Lannett by 4.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 662,422 shares of the company’s stock worth $3,146,000 after purchasing an additional 29,089 shares during the period. JPMorgan Chase & Co. boosted its stake in Lannett by 582.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 684,622 shares of the company’s stock worth $3,251,000 after purchasing an additional 584,343 shares during the period. Jane Street Group LLC bought a new position in Lannett in the 3rd quarter worth approximately $537,000. Finally, Teachers Advisors LLC boosted its stake in Lannett by 64.9% in the 3rd quarter. Teachers Advisors LLC now owns 95,266 shares of the company’s stock worth $453,000 after purchasing an additional 37,492 shares during the period. 81.19% of the stock is owned by institutional investors and hedge funds.

Shares of Lannett stock opened at $7.68 on Friday. The stock has a market capitalization of $335.51 million, a P/E ratio of 2.48 and a beta of 2.40. Lannett has a 1 year low of $3.33 and a 1 year high of $17.15. The company has a current ratio of 2.44, a quick ratio of 1.88 and a debt-to-equity ratio of 2.29.

Lannett (NYSE:LCI) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.68 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.06. The company had revenue of $172.79 million for the quarter, compared to analysts’ expectations of $155.55 million. Lannett had a negative net margin of 39.44% and a positive return on equity of 22.88%. Lannett’s revenue was down .9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.80 EPS. As a group, analysts expect that Lannett will post 2.14 earnings per share for the current fiscal year.

About Lannett

Lannett Company, Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, suspension, soft gel, and injectable dosages.

Recommended Story: What defines an oversold asset?

Analyst Recommendations for Lannett (NYSE:LCI)

Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.